In the current model, atropine reduced EMT in both the chemo-resistant, triple-negative, claudin-low mesenchymal-like breast cancer (MDA-MB-231) cell line and the luminal A epithelial-like cell line (T47D) through the upregulation of the level of E-cad and the reduction of both CD-44 and c-Myc. Here, MYC is linked to breast carcinoma.